Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics operates as a clinical-stage biotechnology company developing viral immunotherapy platforms for solid tumor treatment. The company's news coverage centers on clinical trial developments, regulatory interactions, financing activities, and leadership appointments that shape its path toward potential commercialization of novel cancer therapies.
For biotechnology investors, Candel's news flow typically includes updates on clinical trial enrollments, interim data readouts, and final study results that determine whether investigational therapies advance through development stages. Regulatory milestones such as FDA designations, EMA opinions, and clinical trial authorizations signal progress through the complex approval process for novel oncology treatments. The company also announces financing transactions including registered offerings, term loan agreements, and strategic partnerships that fund ongoing research programs.
This news resource provides coverage of material events disclosed through SEC filings, corporate press releases, and regulatory databases. Expect updates on Phase 2 and Phase 3 trial results, orphan drug designations, breakthrough therapy evaluations, and scientific presentations at oncology conferences. Leadership changes, including appointments of executives with immunotherapy expertise and clinical development experience, often indicate strategic shifts in the company's development priorities.
Tracking Candel Therapeutics news helps investors monitor the progress of specific drug candidates through clinical validation, understand capital allocation decisions, and assess the company's competitive position within the viral immunotherapy sector. Bookmark this page for updates on trial outcomes, regulatory decisions, and corporate developments that influence the company's trajectory.
Candel Therapeutics (Nasdaq: CADL) will host a virtual R&D Event on December 5, 2025 from 11:00 AM–1:45 PM ET. The program includes executive presentations, scientific panels, and collaborator talks offering an extensive overview of Candel’s viral immunotherapy approach and oncology pipeline, including CAN-2409 and CAN-3110 programs.
Featured speakers include CEO Paul Peter Tak, MD, PhD, Nobel Laureate James P. Allison, Carl H. June, MD, and clinical and regulatory leads covering BLA and pre-commercialization roadmaps. Live webcast and replay will be available on the company Investors page with registration required.
Candel Therapeutics (NASDAQ: CADL) reported Q3 2025 results and corporate updates on November 13, 2025. Key clinical progress includes subgroup phase 3 data for CAN-2409 in localized prostate cancer showing improved prostate cancer-specific DFS (HR 0.62; p=0.0046), plans to submit a BLA in Q4 2026, and intent to start a pivotal phase 3 in NSCLC in Q2 2026. Updated survival data for CAN-3110 in recurrent high-grade glioma showed median OS ~11.8–12.0 months in arms A/B. Financially, the company has $87.0M cash (9/30/25) and closed a $130M term loan with $50M drawn at signing to fund operations into Q1 2027.
Candel Therapeutics (Nasdaq: CADL) will present three data sets at SITC 2025 highlighting clinical and preclinical advances in viral immunotherapies and AI‑driven design.
Key points: a Phase 3 study of CAN‑2409 in newly diagnosed, localized prostate cancer met its primary endpoint and the company plans a BLA submission in Q4 2026; Phase 2a MOFA biomarker analysis in NSCLC showed stronger immune activation and prolonged overall survival in non‑squamous vs squamous histology; an AI‑designed candidate (Alpha‑201 IL‑12/15) produced 60.0%±12.6 tumor growth suppression in an EMT6 breast cancer mouse model.
Candel Therapeutics (Nasdaq: CADL) announced that Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO, will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 from 8:00–8:25 AM GMT (4:00–4:25 AM ET). The presentation will be webcast and available under Events and Presentations in the Investors section at www.candeltx.com. A replay will be archived for up to 90 days after the session.
Candel Therapeutics (Nasdaq: CADL) announced the appointment of Bali Pulendran, Ph.D. to its Research Advisory Board on October 16, 2025. Dr. Pulendran is a systems immunology and vaccinology expert, Violetta L. Horton Professor at Stanford, Director of the Institute for Immunity, Transplantation and Infection, and a Thomson Reuters Highly Cited Researcher.
He will advise as Candel advances lead viral immunotherapy candidates CAN-2409 across multiple solid tumors and CAN-3110 for recurrent high-grade glioma, bringing expertise in dendritic cell biology and human immune-response systems.
Candel Therapeutics (Nasdaq: CADL) entered a five-year $130 million term loan facility with Trinity Capital on Oct 14, 2025, with $50 million drawn at closing and access to up to an additional $80 million across three tranches.
The facility carries an initial interest option of 10.25% per annum, a 36-month interest-only period (extendable 12 months upon a commercial milestone), and contains customary covenants and events of default. Candel reported $87.2 million cash as of Sept 30, 2025. Proceeds will refinance an existing loan and fund working capital, initiation of a pivotal phase 3 CAN-2409 NSCLC trial planned for Q2 2026, and prepare for a potential BLA submission in prostate cancer in Q4 2026.
Trinity Capital (Nasdaq: TRIN) committed $130 million in growth capital to Candel Therapeutics (Nasdaq: CADL) on October 14, 2025 to support development of viral immunotherapies.
The funding is earmarked to support clinical development of CAN-2409 and pre-commercial and launch readiness activities for CAN-2409 in prostate cancer pending regulatory approval. Candel's pipeline includes CAN-2409 and CAN-3110 targeting solid tumors (prostate, pancreatic, lung, brain).
Candel has received multiple FDA designations: RMAT for localized prostate cancer, Fast Track for localized prostate and non-small cell lung cancer, and dual Fast Track and Orphan Drug designations for pancreatic and brain cancer programs.
Candel Therapeutics (Nasdaq: CADL) reported encouraging interim phase 1b data for CAN-3110 in recurrent glioblastoma and a related Science Translational Medicine publication on October 8, 2025. Serial multiomic analysis of 97 tumor biopsies from two patients after repeated CAN-3110 dosing showed tumor-to-immune-cell replacement and one complete pathological response despite MRI increases that can mimic progression. Investigators observed expansion of tissue-resident effector memory T cell clonotypes and HLA-presented tumor and viral peptides, supporting viral- and tumor-specific immune activation. Updated median overall survival was 11.8 months (arm A, n=41) and 12.0 months (arm B, n=9). Arm C (n=9) had multiple administrations; no clear benefit beyond 4 injections was seen.
Candel Therapeutics (Nasdaq: CADL) announced it will present multiple updates at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, Nov 5-9, 2025, National Harbor, Maryland. The company will present two poster abstracts on Nov 7: one on its enLIGHTEN Discovery Platform and one on CAN-2409+valacyclovir immune responses in NSCLC. CEO Dr. Paul Peter Tak will give an invited faculty presentation and participate in a panel to present positive phase 3 CAN-2409 data in localized prostate cancer on Nov 7 at 3:55–5:35 p.m.
Candel Therapeutics (Nasdaq: CADL) presented positive Phase 3 clinical trial results for CAN-2409 in localized prostate cancer at ASTRO 2025. The trial, involving 745 patients with intermediate-to-high-risk localized prostate cancer, demonstrated a 30% improvement in disease-free survival (HR 0.7, p=0.0155) and 38% improvement in prostate cancer-specific disease-free survival (HR 0.62, p=0.0046).
Key findings showed CAN-2409's efficacy was consistent across radiation therapy modalities, with significant improvements observed in both moderate hypofractionated EBRT (HR 0.52) and conventional EBRT (HR 0.76). The treatment achieved 80.4% pathological complete response rates compared to 63.6% in the control arm. Grade ≥3 treatment-related adverse events remained similar between treatment and control groups.
The company plans to submit a Biologics License Application in Q4 2026, positioning CAN-2409 as potentially the first major advancement in localized prostate cancer treatment in over 20 years.
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
What is the market cap of Candel Therapeutics (CADL)?
